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Background: Thyroid volume (TV) has been found to be associated with age, anthropometry, smoking, iodine
status and hyperinsulinemia. Hyperinsulinemia is frequent finding in patients with PCOS and has associations with
TV. However, the TV has been evaluated only a few studies in patients with PCOS. Therefore, the aim of this study
was to evaluate the biochemical and hormonal variables in patients with PCOS comparing with the controls and
their relationships between TV.
Methods: This was a case–control study conducted in a training and research hospital. The study population
consisted of 47 reproductive-age PCOS women and 30 control subjects. We evaluated anthropometric, biochemical
and hormonal parameters as well as thyroid volume in PCOS patients and controls. Insulin resistance was calculated
using the homeostasis model assessment insulin resistance index (HOMA-IR).
Results: Mean age, BMI, thyroid stimulant hormone (TSH) levels and TV were similar between groups (p<0.05). The
HOMA-IR and free T4 levels were higher in patients with PCOS. However, hyperinsulinemia and insulin resistance
were not found to be associated with TV. Thyroid volume was positively correlated with the LH and anti TPO levels.
The participants were divided into 2 groups according to HOMA-IR levels. The mean TV measurement was higher
in group with higher HOMA-IR levels, but the difference was not significant in young age PCOS patients.
Conclusion: In early age PCOS patients it was observed that insulin resistance had no effect on TV. In this case, anti
TPO and LH have dominant effect on TV. Chronic stimulation with LH and insulin may lead to increase in TV in later
stages of the PCOS diseases.
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Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorder affecting at least 5 to 10%
of women of reproductive age [1]. PCOS is characterized
by hyperandrogenism, menstrual disturbance, anovula-
tion, infertility and obesity [2] and is reported to be asso-
ciated with an increased risk of cardiovascular disease
(CVD) [3] and early atherosclerosis [4]. Hyperinsuline-
mia and insulin resistance are frequent findings in
patients with PCOS and have associations with thyroid
volume and nodular thyroid diseases [5].* Correspondence: drevrimcakir@gmail.com
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reproduction in any medium, provided the orIn recent studies, thyroid volume (TV) has been found
to be associated with age, anthropometry, smoking, iod-
ine status and hyperinsulinemia [5-8]. Additionally,
growth hormone and growth factors such as insulin like
growth factor, epidermal growth factor have been shown
to affect TV [9,10]. Furthermore, endogen TSH stimula-
tion has been shown to increase thyroid gland size [11].
Luteinizing hormone is a glycoprotein hormone like
TSH and has similar alpha subunit. Additionally, the LH
has been identified to increase thyroid adenylate cylase
activity [12,13]. It has been known that the LH levels are
higher in patients with PCOS compared with the con-
trols even in follicular phase [14,15].
The goiter prevalence is more common in women
than in men regardless of population [16]. The higher
incidence of thyroid diseases in women is previouslyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been shown to enhance proliferative and mitogenic ac-
tivities of thyroid cells [17,18]. But, in recent years
chronic estradiol treatment has been shown to reduce
volume densities of follicles, follicular epithelium and
thyroid gland [19,20].
Therefore, the aim of this study was to evaluate the
biochemical and hormonal variables in patients with
PCOS and their relationships between TV.Materials and methods
We studied 47 patients with PCOS and 30 age- and
body mass index (BMI) - matched healthy controls. We
studied in a mild iodine deficiency area. The protocol
was approved by the local ethics committee. All patients
gave a written consent. All patients were female and
non-smokers. This was a prospective case–control study
conducted in a training and research hospital between
September 2011-March 2012.
The diagnosis of PCOS was made according to the
Rotterdam European Society for Human reproduction
and Embryology/American Society for Reproductive
Medicine–sponsored PCOS Consensus Workshop Group
[21]. The revised diagnostic criteria of PCOS are as
follows, with at least two of the following being
required;
1. Oligo and/or anovulation that is menstrual
disturbance
2. Clinical and/or biochemical signs of
hyperandrogenism
3. Polycystic ovarian appearance on ultrasound
The control group (n=30) consisted of healthy patients
who were admitted to check-up unit without any sys-
temic disorder. All of the women in the control group
had hirsutism score <8. All women in the control group
had regular menses, every 21–35 days. None of the
women in the control group had polycystic ovary on
ultrasound.
Those participants who had a smoking history, diabetes
mellitus, hyperprolactinemia, congenital adrenal hyperpla-
sia, androgen-secreting tumours, thyroid disorders includ-
ing thyroid parenchyma heterogeneity and/or nodular
disease on ultrasound and/or thyroid function abnormal-
ities, Cushing syndrome (1 mg dexamethasone suppression
test was done all PCOS patients and obese control who
had a BMI greater than 30), infection diseases, hyperten-
sion, hepatic or renal dysfunction were excluded from the
study. The participants under the age of 18 and over the
age of 35 were excluded from the study. The participants
were also excluded if they had used confounding medica-
tions, including oral contraceptive agents, antilipidemicdrugs, hypertensive medications, and insulin-sensitizing
drugs, within 3 months before enrolment.
Weight and height were measured in light clothing
without shoes. The BMI was calculated by dividing the
weight by the square of the height (kg/m2). The waist
circumference was measured at the narrowest level
between the costal margin and iliac crest, and the hip
circumference was measured at the widest level over the
buttocks while the subjects were standing and breathing
normally. The waist-to-hip ratio (WHR) was then
calculated.
The degree of hirsutism was determined by the
Ferriman-Gallwey (FG) score [22]. The BMI, WHR and
hirsutism scores were assessed by a single investigator
for all of the subjects.
Biochemical evaluation
Venous blood samples were obtained in the follicular
phase of a spontaneous or progesterone-induced men-
strual cycle. Before the study, blood samples were drawn
from each patient after a 12h overnight fasting for the de-
termination of the hormones, lipid profile, high-sensitive
C- reactive protein (hs-CRP), insulin and glucose levels.
Plasma glucose was determined by the glucose oxidase/
peroxidase method (Gordion Diagnostic, Ankara, Turkey).
The serum levels of follicle-stimulating hormone (FSH),
luteinizing hormone (LH), prolactin, dehydroepiandroster-
one sulphate (DHEAS), total testosterone (T), insulin, free
thyroxin (fT4), thyroid stimulating hormone (TSH) and
thyroid peroxidase anti-body (anti-TPO) were measured
with specific electrochemiluminescence immunoassays
(Elecsys 2010 Cobas, Roche Diagnostics, Mannheim,
Germany). The levels of total-cholesterol, high density
lipoprotein cholesterol (HDL-C), and triglyceride (TG)
were determined with enzymatic colorimetric assays by
spectrophotometry (BioSystems S.A., Barcelona, Spain).
The low density lipoprotein cholesterol (LDL-C) level was
calculated using the Friedewald formula.
Serum hs-CRP was determined using high-sensitive
CRP immunonephelometry (BN, Dade-Behring; Marburg,
Germany).
Insulin resistance was calculated using the homeostasis
model assessment insulin resistance index (HOMA-IR)
[23], according to the following formula: fasting plasma
glucose (mmol/L) × fasting serum insulin (mU/mL)/22.5.
The cut-off value was taken as 2.7 for HOMA-IR [24].Thyroid volume (TV)
Thyroid volume was assessed using a high-resolution
ultrasound machine (Hitachi, Japan; EUB 7000) with a
6–14 megahertz high-frequency linear transducer. Thy-
roid volumes were calculated by multiplication of three
diameters and the constant value 0.52.
Table 2 The hormonal value and tyroid volume levels in
women with polycystic ovary syndrome (PCOS)
and healthy controls
PCOS Control P
(n = 47) (n = 30)
fT4 1.22±0.24 1.07± 0.16 0.007
TSH, μ IU/ml 2.01± 1.19 1.98± 1.04 0.892
FSH, m IU/ml 5.57±2.48 6.06±2.03 0.377
LH, m IU/ml 6.63±2.69 5.12±2.66 0.121
Estradiol, pg/ml 67.71±90.85 84.48±49.16 0.007
Total Testosterone, ng/ml 0.48±0.21 0.41±0.11 0.09
PRL, ng/ml 20.6±13.03 12.15±5.84 0.04
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Collected data were entered to SPSS version 17. Con-
tinuous data were shown as means ± SD. Chi-squared
tests were used to compare differences in rates. Nor-
mally distributed variables were compared using the Stu-
dent T test; nonnormally distributed variables were
compared by the Kolmogrow Smirnov Test. The degree
of association between continuous variables was calcu-
lated by the Pearson correlation coefficient. The multiple
linear regression using the stepwise method was used to
determine the independent predictors.
A p value lower than 0.05 was accepted as statistically
significant.
DHEAS, μq/dl 274.3±142.3 182.23±77.6 0.002
Thyroid volume, ml 10.13±3.98 10.46±4.36 0.734
fT4: free thyroxine; TSH: thyroid stimulating hormone; FSH: follicule stimulating
hormone; LH: luteinizing hormone; PRL: prolactin; DHEAS:
dehydroepiandrosterone sulfate.Results
Clinical, biochemical and hormonal parameters were
screened in the patients with PCOS and in the healthy
control subjects (Table 1). We studied 47 patients with
PCOS (mean age 23.27 ± 5.83 years, range 18–33 years;
BMI, 24.41± 4.39 kg/m2) and 30 age- and BMI- matched
healthy controls (mean age 22.80±4.4 years, range 18–32
years; BMI, 23.64±3.35 kg/m2).Comparing parameters between groups
The mean fasting glucose, insulin, HOMA-IR, triglycer-
ide, hsCRP, DHEAS, prolactin, fT4 levels were signifi-
cantly higher and the estradiol levels were significantly
lower in the patients with PCOS (p<0.05) (Tables 1, 2).
The mean TV was 10.13±3.98 mL in PCOS patients
while 10.46±4.36 mL in healthy control women
(p=0.734). The number of anti-TPO positive women was
similar between groups (p: 0.456).Table 1 The clinic and biochemical data in women with
polycystic ovary syndrome (PCOS) and healthy controls
PKOS Control P
(n =47) (n=30)
Age, year 23.27±5.83 22.80±4.4 0.704
BMI, kg/m2 24.41±4.39 23.64± 3.35 0.412
Fasting glukose, mg/dL 94.63±11.01 87.66±9.59 0.006
Fasting insülin, μ IU/mL 15.44± 7.98 11.34±5.52 0.017
HOMA-IR 2.22± 1.89 1.46±0.69 0.034
Total cholesterol, mg/dL 170.46±26.9 156.06±27.3 0.101
Triglyceride, mg/dL 109.29±59.46 89.13±52.82 0.05
HDL-C, mg/dL 54.21±12.12 53.31±14.52 0.771
LDL-C, mg/dL 95.09±23.54 84.58±24.18 0.128
hsCRP, mg/L 2.83±4.6 1.35±1.81 0.03
HOMA-IR: homeostasis model assessment insulin resistance index; HDL-C: high
density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol;
hs-CRP: high-sensitive C- reactive protein.The correlations between TV, biochemical and hormonal
parameters
A significant positive correlation was found between the
TV, anti-TPO and LH (r: 0.602, p<0.0001; r: 0.316,
p: 0.007). However, hyperinsulinemia and insulin resist-
ance were not found to be associated with TV. In mul-
tiple linear regression analyses TV was significantly
associated with LH (beta coefficient=0.377, p<0.001),
anti-TPO (beta coefficient=0.444, p<0.001) and TSH
(beta coefficient= −0.309, p=0.004) (age, BMI, FSH, es-
tradiol and HOMA-IR were included in the model).Comparing the TV and hormonal parameters in groups
based on the HOMA-IR
The participants were divided into 2 groups according
to HOMA-IR levels. The cut-off point was 2.7 [24].
Those participants who had a HOMA-IR greater than
2.7 had significantly higher hsCRP levels. Although, the
mean TV measurement was higher in group with higher
HOMA-IR levels, the difference was not statistically
significant (Table 3).Table 3 The biochemical, hormonal value and thyoid
volume in HOMA-IR groups
HOMA-IR<2.7 HOMA- IR≥2.7 P
fT4, ng/Dl 1.14±0.19 1.17±0.22 0.667
TSH, μ IU/ml 1.84±0.99 2.25± 1.47 0.170
hsCRP, mg/L 1.8±4.43 2.22±2.34 0.05
FSH, m IU/mL 5.58±2.35 6.16±2.30 0.322
LH, m IU/mL 6.09±3.93 6.44±4.99 0.735
Thyroid volume, mL 10.44±3.30 10.70±5.09 0.802
fT4: free thyroxine; TSH: thyroid stimulating hormone; hsCRP: high-sensitive
C- reactive protein; FSH: follicule stimulating hormone; LH: luteinizing
hormone.
Cakir et al. Journal of Ovarian Research 2012, 5:43 Page 4 of 6
http://www.ovarianresearch.com/content/5/1/43The correlation between LH and TV was shown in
Figure 1.
Discussion
The results of the present study demonstrate that the
mean TV measurements were similar in the early age of
PCOS patients and the control group. Furthermore,
insulin resistance had no effect on TV in the early age
participants. However, the TV showed a significant cor-
relation with LH and anti-TPO.
It has been shown that insulin had mitogenic effect on
thyrocyte. Additionally, in recent studies hyperinsuline-
mia and insulin resistance has been found to be asso-
ciated with TV [5,25]. However, in the present study
hyperinsulinemia and insulin resistance were not found
to be associated with TV. But, when we divided partici-
pants into 2 groups according to the presence of insulin
resistance, we observed the higher TV measurements in
insulin resistant group, but the difference was not statis-
tically significant. It is thought to be due to lean and
young participants.
Human chorionic gonadotropin (hCG) secreting pla-
cental tumours such as hydatidiform moles and chorio-
carcinomas have been found to be associated with
hyperthyroidism [26]. Furthermore, the HCG has been
reported to increase TSH receptor expression, thyroid
hormone secretion, iodide uptake, organification, adenylateFigure 1 The relationship between total thyroid volume and luteinizicyclase, and deoxyribonucleic acid synthesis in rat and also
cultured human thyrocytes [27-29].
Luteinizing hormone is a glycoprotein hormone like
TSH and has similar alpha subunit. In Carayon et al.
study LH has been identified to increase thyroid adenyl-
ate cylase activity 65 times more potently than HCG in
human thyroid membranes [12]. Also, in Yoshimura
et al. study human LH has been found to be more po-
tent than HCG in binding to the TSH receptor and
stimulating adenylate cyclase [13].
As mentioned, HCG and LH have thyrotrophic effect
in rat and human thyroid membrane. In present study,
in consistent with these studies LH was positively corre-
lated with TV and in regression analyses LH was
obtained to be an independent risk factor for increased
TV, regardless of age, BMI and anti TPO.
The higher incidence of thyroid diseases in women is
previously attributed to the higher estradiol levels. Estra-
diol has been shown to enhance proliferative and mito-
genic activities of thyroid cells [17,18]. However, recently
it has been shown that chronic estradiol treatment led to
significant decreases in volume densities of thyroid folli-
cles, follicular epithelium and epithelial height [19]. In
another study 3712 women were evaluated and found
that oral contraceptives were related with a lower thy-
roid volume and reduced risk of goiter. In this study the
oral contraceptives users had goitre four times moreng hormone.
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sion with oral contraceptives might be the factor for
decreased thyroid volumes consistent with the present
results. This suggests to us, endogenous elevated estra-
diol levels lead to increases in thyroid volume, while
exogenous estradiol treatment leads to decreases in thy-
roid volume probably as a result of LH suppression.
The present study clearly shows that increased LH
levels are associated with increased TV. Furthermore,
anti-TPO, TSH and LH levels were found to be inde-
pendent risk factors for increased TV. However, the lack
of the association between insulin and TV might be due
to lean and early age PCOS patients as well as short dis-
ease duration. Chronic stimulation with LH and insulin
may lead to increase in TV in later stages of the PCOS
diseases.
The study has some limitations. The sample size was
small and the participants were lean and young age. The
women with PCOS had higher LH levels in comparison
to controls; however the difference was not significant
which might be related to small sample size. Therefore,
the further case control clinical studies are needed to
evaluate the association between the gonadotropins and
the TV.
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